Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
3
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Fludarabine
Research Leaders
9 sponsors active, led by The First Affiliated Hospital of Soochow University
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Research Network
Common Treatments
- Fludarabine1
- Js203 For Injection1
- Selinexor1
- Chimeric Antigen Receptor T Cells Cart Targeting Igβ Targets1
Active Sponsors
- The First Affiliated Hospital of Soochow University2
- Yixing People's Hospital1
- The General Hospital of Western Theater Command1
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
- Shanghai Junshi Bioscience Co., Ltd.1
Top Investigators
The First Affiliated Hospital of Soochow University
Peking University Cancer Hospital & Institute